ResearchStrata · Volume I
Strata
Volume I · Pharmaceutical patents in India, 2005–2016. Depth is time, height is the court, and each doctrine has its own lane.
15 cases9 threadsYears 2005–2016
Appeal dismissed or decision upheld The same matter Reversed: the thread is cut
Pilot. Dates, holdings and every thread are to be checked against the judgments by the Strata team before this volume is cited.
All cases as a list
Section 3(d)
Application refused, among other grounds under section 3(d): the beta-crystalline form was a new form of a known substance without enhanced efficacy.
Section 3(d) upheld against the challenge that it was vague and arbitrary under Article 14; the Court declined to decide its compatibility with TRIPS.
The invention was found novel and inventive, but the refusal was upheld under section 3(d).
Beta-crystalline imatinib mesylate fails section 3(d). For a medicine, ‘efficacy’ means therapeutic efficacy, and physical properties such as better flow or bioavailability alone do not show it.
Compulsory licences
India’s first compulsory licence, for sorafenib tosylate: all three grounds in section 84(1) were found made out. Royalty set at 6 per cent.
Application for a compulsory licence rejected: no prima facie case that BDR had made reasonable efforts to obtain a voluntary licence.
The licence upheld; the royalty raised to 7 per cent.
Bayer’s writ petition dismissed; the compulsory licence stands.
Special leave petition dismissed.
Application for a compulsory licence rejected.
Infringement
Interim injunction against Cipla’s generic erlotinib refused; the public interest in access to an affordable life-saving drug weighed in the balance.
Roche’s appeal dismissed; refusal of the interim injunction upheld.
After trial: the patent was held valid, but Cipla’s product (the polymorph B form) was held not to infringe it.
Injunction granted against Glenmark’s sitagliptin products.
Reversed on infringement: Cipla’s erlotinib was held to infringe Roche’s patent.

